METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Tracking advanced prostate cancer treatment in real patients
Disease control OngoingThis study observes how well apalutamide controls prostate cancer in real-world patients who have already chosen this treatment with their doctor. Researchers will track 170 men with metastatic prostate cancer that still responds to hormone therapy, monitoring their PSA levels an…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Targeted prostate cancer trial for hispanic and black men withdrawn before start
Disease control TerminatedThis study aimed to test a combination of two drugs, niraparib and abiraterone, plus a steroid, in men with newly diagnosed, advanced prostate cancer that had spread and had specific genetic changes. It specifically sought Hispanic/Latino and non-Hispanic Black participants to se…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE2 • Sponsor: Qian Qin • Aim: Disease control
Last updated Mar 09, 2026 14:23 UTC
-
Doctors test High-Tech scans to monitor prostate cancer
Knowledge-focused OngoingThis study aims to learn if a special type of scan called a PSMA-PET can be used to monitor how well treatment is working for men with metastatic prostate cancer that still responds to hormone therapy. Twenty participants will receive standard treatment and undergo two of these s…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:43 UTC
-
Researchers track heart safety of prostate cancer drug in real patients
Knowledge-focused OngoingThis study is collecting safety information on an approved prostate cancer drug combination in Japanese men. Researchers will observe about 100 participants already receiving darolutamide plus standard hormone therapy and chemotherapy in their normal medical care. The main goal i…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:57 UTC
-
Scientists probe if common prostate cancer drugs make tumors 'Glow' brighter on scans
Knowledge-focused OngoingThis small, early study aims to understand if standard hormone therapy drugs change how prostate cancer appears on a specialized PSMA PET scan. About 15 men with recurrent prostate cancer will receive a standard hormone pill and have two scans over four weeks. The goal is to gath…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: EARLY_PHASE1 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Knowledge-focused
Last updated Mar 17, 2026 12:55 UTC